CAI International, Inc. Earnings Recaps
Q2 2026
Aug 8, 2026
Caris Life Sciences shares surged 24.2% following Q2 results as strong case volume growth and early enthusiasm for the Caris Detect multi-cancer early detection (MCED) test significantly exceeded investor expectations.
Key takeaways
- Total cases reached a record 59,200 in Q2, representing an 18% year-over-year increase, driven by both tissue and blood testing volumes.
- Over 345,000 clinical oncology tests were performed, including more than 114,000 Whole Exome and Whole Transcriptome tests.
- The proprietary database grew to over 1.13 million profiled patients, supporting Caris' AI-driven comprehensive molecular oncology platform.
- Caris Detect MCED test drew physician and patient interest surpassing management’s own forecasts, with near-term demand potentially outpacing rollout capacity.
- Expansion of the Precision Oncology Alliance added key members, strengthening commercial reach and collaborative research.
Q3 2025
Nov 6, 2025
Caris Life Sciences delivered exceptional third-quarter results, with revenues soaring 113% year-over-year to $216.8 million, reflecting strong demand in molecular profiling services and significant margin improvements.
Key takeaways
- Molecular profiling services revenues shot up 121% year-over-year to $207.6 million, supported by a robust increase in clinical case volumes and average selling prices (ASP).
- Clinical case volumes reached nearly 51,000, marking 18.2% growth, while ASP rose to $4,089 per profile, up 87% year-over-year, driven by changes in reimbursement rates.
- Gross margins improved dramatically to 68% from 43.7% in Q3 2024, aided by operational efficiencies and strong revenue growth.
- Positive adjusted EBITDA of $51.2 million and net income of $24.3 million underscore a significant milestone in profitability.
- Cash on hand increased to nearly $760 million, providing strategic flexibility for future investments in technology and early detection markets.